|08/03/17||vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon|
|HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 3, 2017--
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S.
Patent and Trademark Office has issued a patent with claims protecting
methods of treatment using azeliragon, the Company’s oral antagonist of
the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of
mild Alzheimer’s disease. The patent number is 9,717,710 (‘710 Patent).
The ‘710 Patent, expiring in October 2034, inc... |
|08/02/17||vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results|
|HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 2, 2017--
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today provided a corporate
update and reported financial and operational results for the second
quarter ended June 30, 2017.
“With positive progress in our lead Alzheimer’s and diabetes programs,
vTv is pleased to showcase another productive quarter,” said Steve
Holcombe, president and CEO of vTv Therapeutics. “At the American
Diabetes Association ... |
|07/13/17||vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference|
|HIGH POINT, N.C.--(BUSINESS WIRE)--Jul. 13, 2017--
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that data on
the company’s phase 3 Alzheimer’s candidate, azeliragon, an oral
antagonist of the Receptor for Advanced Glycation Endproducts (RAGE),
will be presented at the 2017 Alzheimer's Association International
Conference (AAIC) held in London, England, July 16 – 20, 2017.
Details of the poster presentations are listed below:
|06/11/17||vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions|
|Lower doses of TTP273 may demonstrate a more pronounced reduction in
HbA1c and other key endpoints
HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 11, 2017--
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that results
from a Phase 2 clinical study of TTP273, an investigational, oral small
molecule GLP-1 receptor (GLP-1R) agonist for the treatment of Type 2
diabetes, were presented at the American Diabetes Association 77th Scientific